Results 131 to 140 of about 157,873 (262)

Optimizing Research Operations and Resource Utilization in ALS Care: Insights From the Tofersen Antisense Oligonucleotide Expanded Access Protocol

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Tofersen is a gene‐targeted therapy for individuals with superoxide dismutase 1 (SOD1) (+) amyotrophic lateral sclerosis (ALS). Prior to U.S. Food and Drug Administration (FDA) approval, tofersen was made available through expanded access protocol.
Alison Wheeler, Kush Mehta, Danica Sanders, Cathy Chin, Hannah Zivalic, Judith Carey, Alexandra McCaffrey, Pravin Pant, Carl Lewenhaupt, Sarah Luppino, Gabriel Jacobs, Shea Golden, Ryan Gifford, Erica Scirocco, Mackenzie Keegan, Munaf Hatem, Taravat Yazdanian, Sanem P. Uysal, Natalie Susco, Shauna Schwartzman, Karen Branch, Kathryn E. Hall, Joanna Barnas, Jenny Lam, Jennifer Hagar, Carol Ann Hannan, Sabrina Paganoni, James D. Berry, Mark Garret, Jennifer Scalia, Suma Babu   +30 more
wiley   +1 more source

Medical Claim Costs of Facioscapulohumeral Muscular Dystrophy in the United States. [PDF]

Clinicoecon Outcomes Res
Hill AA, Kinoshita J, Deypalan MN, Kolocha M, Hung M, Hon E, Sarraille W, Winegarden W, Ghanjanasak T, Arjomand J.   +9 more
europepmc   +1 more source

Mismatch Between the Distribution of Neuromuscular Specialists and Myasthenia Gravis Patients in the US Medicare Fee‐for‐Service Population

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims There is a mismatch between clinical need and access to neurologists across the US. Myasthenia gravis (MG) incidence and prevalence are increasing, particularly in US patients older than 65 years, raising concern for access to neuromuscular specialists that represent only 4% of neurologists.
Lauren Herrera, David Bruckman, Ikjae Lee, Jesse D. Schold, Benjamin Claytor, Nicholas Silvestri, Yuebing Li, Michael K. Hehir   +7 more
wiley   +1 more source

Medicare costs and home time loss among fee-for-service beneficiaries by frailty and dementia status. [PDF]

J Frailty Aging
Sison SDM, Zhong L, Oh G, Shi SM, Park CM, Olivieri-Mui B, McCarthy EP, Kim DH.   +7 more
europepmc   +1 more source

Capturing Financial Burden Concerns in an ALS Multidisciplinary Clinic

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Amyotrophic lateral sclerosis (ALS) is associated with substantial financial burden. How financial concerns are documented or addressed in ALS multidisciplinary clinics (MDC) is unclear. We aimed to characterize financial concerns among people living with ALS (pALS) and how they are identified and documented by ...
Nikhita Pathapati, Minh Nguyen, Jaden Ju, Mahita Maddukuri, John Kiehl, Elizabeth Kvale, Aaron P. Thrift, Sarah Berth, Astrid Grouls   +8 more
wiley   +1 more source

Changes in Medication Use After Medicare Part D Annual Out-of-Pocket Spending Caps.

JAMA Health Forum
Cai CL, Anderson KE, Kesselheim AS, Rome BN.   +3 more
europepmc   +1 more source

State Expansions in Medicaid Financial Assistance for Low-Income Medicare Beneficiaries: Changes in Enrollment and Use. [PDF]

Health Serv Res
Fung V, Cheng D, Price M, Khong K, Yang Z, Marcondes FO, Koma JW, Hsu J, Alegria M, Newhouse JP.   +9 more
europepmc   +1 more source

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, EarlyView.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source

Sacral Neuromodulation in the Management of Refractory Pediatric Lower Urinary Tract Dysfunction

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Sacral neuromodulation is currently used in the pediatric patient population for refractory lower urinary tract dysfunction (LUTD). Evidence, however, is currently limited for institutional experiences of long‐term outcomes for sacral neuromodulation in the pediatric patient population.
Megan A. Stout, Lauren E. Corona, Li‐Ching Huang, Tatsuki Koyama, Lindsay A. Gil, Shelly King, Benjamin M. Whittam, Seth A. Alpert, John C. Pope   +8 more
wiley   +1 more source

Prior Authorization for Sacral Nerve Stimulation in the Era of WISeR: Evaluation of U.S. Payer Coverage Policies

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Sacral nerve stimulation (SNS) is an established therapy for refractory urinary incontinence, yet the 2025 Wasteful and Inappropriate Service Reduction Model (WISeR) designated it as requiring mandatory prior authorization. No analysis has examined how U.S.
Thriaksh Rajan, Andre Revnew, David Sheyn, Adonis Hijaz, Ramy Abou Ghayda   +4 more
wiley   +1 more source